New PET scan could spot hidden aggressive prostate cancer in men avoiding treatment

NCT ID NCT07285057

Recruiting now Diagnosis Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether adding a special PET scan (using a radioactive tracer called flotufolastat F18) to the standard MRI can better find aggressive prostate cancer in men who are currently on active surveillance. About 120 men with low- or favorable intermediate-risk prostate cancer will get both scans before a confirmatory biopsy. The goal is to see if the PET scan catches cancers that MRI misses, helping doctors decide who truly needs treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Flotufolastat F18 (POSLUMA®), a radioactive tracer used in PET/CT imaging
What this could lead to: If successful, this could lead to a more accurate imaging method to detect aggressive prostate cancer early, helping men on active surveillance avoid unnecessary biopsies or delayed treatment.
What could go wrong: This is a small, early-phase study (120 participants) at a single center. The imaging agent is already FDA-approved, but its added benefit over standard MRI is unproven, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA PROSTATE CANCER PROSTATIC NEOPLASMS

Contacts and locations

Locations

Mount Sinai Hospital / Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.